4 quarters tracked · Beat rate 100% · Updated quarterly
| Period | Report Date | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | $6.73 | $8.55 | +27.0% | Beat |
| Q4 2025 | 2025-12-31 | $6.74 | $7.54 | +11.9% | Beat |
| Q3 2025 | 2025-09-30 | $5.75 | $7.02 | +22.0% | Beat |
| Q2 2025 | 2025-06-30 | $5.51 | $6.31 | +14.5% | Beat |
Earnings Beat Rate
Eli Lilly and Company has beaten analyst EPS estimates in 4 of 4 tracked quarters (100% beat rate). Data sourced from SEC filings and analyst consensus. View full AI analysis →